NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting immunoregulatory cytokines and identifying and eliminating autoreactive T cells that contribute to neuroinflammation.

SNK01 autologous NK cell therapy demonstrated a positive effect on improving cerebral spinal fluid (“CSF”) and plasma levels of Tau, amyloid, and alpha-synuclein proteins in Alzheimer’s patients suggesting a potential larger application in the treatment of other neurodegenerative diseases associated with these proteins.

90% of patients enrolled in the proof-of-concept Phase 1 Alzheimer’s trial had improved or stable cognitive function at week 11 using the composite ADCOMS score.

SNK01 was also found to reduce neuroinflammation, showing improved levels of Glial Fibrillary Acid Protein (GFAP) in most patients, Neurofilament-light (NfL), Growth/Differentiation Factor-15 (GDF15), and Latent Transforming Growth Factor Beta Binding Protein 2 (LTBP2), suggesting a potential preventative clinical application for SNK01.

NKGen submitted an IND for SNK01 in Parkinson’s disease (“PD”) in Q1 2024 and anticipates to begin enrollment for its Phase 2 trial in advanced Alzheimer’s disease (“AD”) in Q2 2024.

SANTA ANA, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced the details disclosed in today’s presentation by Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, entitled “Evaluating Adoptive Cellular Immunotherapy for Neurodegeneration with Autologous SNK01”, in which the Company shared additional information on the scientific rationale, preclinical and clinical data to date on the use of SNK01 enhanced NK cell therapy in patients with advanced AD and PD.

The presentation highlighted preclinical data showing the ability of SNK01 to phagocytose and digest both amyloid and alpha-synuclein proteins, the ability to secrete cytokines, which are able to inactivate inflammatory cells, as well as the ability to reduce autoreactive T cells, which have been implicated as a significant contributor to neuroinflammation and damage. In addition, compassionate use case studies of patients with advanced Alzheimer’s disease and Parkinson’s disease treated with SNK01 were presented as well as an update from the Company’s Phase 1 Alzheimer’s trial.